LL-37

What it is

LL-37 is a 37-amino-acid peptide released from the human cathelicidin precursor hCAP18. Its name reflects its starting leucine residues and peptide length.

It interacts with microbial membranes and host immune pathways in laboratory systems. Depending on context, LL-37 can amplify rather than dampen inflammation.

Why people ask about it

People ask about LL-37 because of its role in innate immunity and publications examining chronic wound environments.

What the science says

Randomised human studies have examined topical LL-37 in venous leg ulcers, with findings dependent on formulation and study population. Those limited studies do not establish benefit for injectable use or general immune enhancement.

Is it right for me?

For LL-37, an online consultation and clinician approval precede payment, with particular attention to skin diagnosis and the proposed route of use.

How Welcuren works

Complete a short online consultation about your health and goals.

A clinician reviews your answers, may ask follow-up questions, and decides whether this treatment is appropriate for you.

You only pay once treatment is approved. Our licensed facility then dispatches it with full instructions, on tracked global delivery.

Safety

Local irritation and inflammatory responses are concerns, and systemic exposure has an uncertain safety profile. Psoriasis, autoimmune disease, pregnancy and breastfeeding warrant specific review because LL-37 participates in immune signalling; your clinician will advise